Patients’ resistance to heparin therapy may occur in different circumstances: heparin pseudo-resistance, antithrombin III (ATIII) deficiency, low heparin concentration, and COVID-19-related heparin resistance. Here, SERPINC1 is linked to hyperinsulinemic hypoglycemia, familial, 4.